Figure S2 from A Somatostatin Receptor Subtype-3 (SST&lt;sub&gt;3&lt;/sub&gt;) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

Mari C. Vázquez‐Borrego(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raúl M. Luque(Instituto de Salud Carlos III), Rosa Ortega‐Salas(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Álvaro Toledano-Delgado(Instituto Maimónides de Investigación Biomédica de Córdoba), Miguel Á. Japón(Instituto de Biomedicina de Sevilla), Alexandre Vasiljevic(Centre de Recherche en Neurosciences de Lyon), Eva Venegas‐Moreno(Hospital Universitario Virgen del Rocío), Michael D. Culler(Ipsen (United States)), Heather Halem(Ipsen (United States)), Gérald Raverot(Université Claude Bernard Lyon 1), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Cristóbal Blanco-Acevedo(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), David A. Cano(State University of New York), Alfonso Soto‐Moreno(Instituto de Biomedicina de Sevilla), Jason Hill(Biotechnology Institute), Vandana Gupta, Shengwen Zhang(Indiana University School of Medicine), Juan Solivera(Instituto Maimónides de Investigación Biomédica de Córdoba), Ana Barrera-Martín(Instituto Maimónides de Investigación Biomédica de Córdoba), María A. Gálvez(Hospital Universitario Reina Sofía), Marcelo Páez-Pereda(Essen BioScience (United States))

Unknown

March 31, 2023

Cited by 0